… Abstract: Background: Anti-tumor necrosis factor (anti-TNF) … Characteristics of the main
randomized controlled trials … 21 (5.3%) patients had infusion reactions leading to drug withdrawal …

… Other molecular aspects of pharmacology, which add an additional layer of complexity to …
to be resolved after discontinuation of the drug. Paradoxically, anti-TNF-α agents have been …

… of biosimilars of the anti-TNF agents allow drug costs to be … used in all patients initiating an
anti-TNF agent as a means to … dosing based on clinical features (the maintenance phase). In …

… 2016 the US Food and Drug Administration (FDA) registered biosimilar infliximab for all …
countries employ demand-side incentives to encourage the uptake of biosimilars. In the US, …

… biosimilar drug, extensive comparability exercises, including physicochemical characteristics
… ): A total of 459 patients were naïve to anti-TNF-α therapy, 196 had a previous exposure to …

… Anti- tumor Necrosis Factor (anti-TNF) agents are the … were receiving the reference drug
or the biosimilar. Citation66 … on the common aspects between biosimilars and biological RPs …

… the role of biosimilars in inflammatory bowel disease in terms … in patients has the potential
for large drug-acquisition cost-… and biological characteristics of the infliximab biosimilar SB2, …

… of inflammatory bowel disease (IBD), both in Crohn’s disease (… anti-tumor necrosis factor α
(anti-TNF) antibody of IgG1 isotype [3]… , and pharmacological characteristics of CT-P13, both in …

… diseases, included Crohn’s disease, ulcerative colitis, psoriatic arthritis and chronic plaque
psoriasis. In Table 1 we present the general characteristics … , for inflammatory bowel disease, …

… of biosimilars with a similar side-effect profile to biologics. This review discusses the history
of biosimilars in … a step-wise drug failure before they approve of the use of anti-TNF-α agents. …